Allelotyping of anaplastic thyroid carcinoma: Frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q

Genes Chromosomes and Cancer

Volumn 27, Issue 3, 2000, Pages 244-251

  Kitamura, Yutaka ^a   Shimizu, Kazuo ^a   Tanaka, Shigeo ^a   Ito, Koichi ^b   Emi, Mitsuru ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b ITO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSATELLITE DNA;

ALLELE; ANAPLASTIC CARCINOMA; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; PATHOGENESIS; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 19; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; THYROID NEOPLASMS;

EID: 0033963995     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(200003)27:3<244::AID-GCC4>3.0.CO;2-7     Document Type: Article

References (42)

1. Bethwaite PB, Koreth J, Herrington CS, McGee JO. 1995. Loss of heterozygosity occurs at the D11S29 locus on chromosome 11q23 in invasive cervical carcinoma. Br J Cancer 71:814-818.
2. Bongarzone I, Pierotti MA, Monzini N, Mondellini P, Manenti G, Donghi R, Pilotti S, Grieco M, Santoro M, Fusco A, Vecchio G, Della Porta G. 1989. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 4:1457-1462.
3. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D. 1994. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415-416.
4. Cairns P, Okami K, King P, Bonacum J, Ahrendt S, Wu L, Mao L, Jen J, Sidransky D. 1997. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res 57:5356-5359.
5. Caldas C, Hahn S, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. 1994. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32.
6. Califano JA, Johns MM III, Westra WH. 1996. An allelotype of papillary thyroid cancer. Int J Cancer 69:442-444.
7. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH. 1990. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520.
8. Carcangiu ML, Steeper T, Zampi G, Rosai J. 1985. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 83:135-158.
9. Chakrabarti R, Srivatsan ES, Wood TF, Eubanks PJ, Ebrahimi SA, Gatti RA, Passaro E Jr, Sawicki MP. 1998. Deletion mapping of endocrine tumors localizes a second tumor suppressor gene on chromosome band 11q13. Genes Chromosomes Cancer 22:130-137.
10. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ. 1997. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404-407.
11. Donghi R, Longoni A, Pilotti S, Michieli P, Porta GD, Pierotti M. 1993. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753-1760.
12. Fagin JA. 1992. Molecular defects in thyroid gland neoplasia. J Clin Endocrinol Metab 75:1398-1400.
13. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. 1993. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184.
14. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-767.
15. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. 1996. Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747.
16. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. 1999. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 59:1811-1815.
17. Harada T, Ito K, Shimaoka K, Hosoda Y, Yakumaru K. 1977. Fatal thyroid carcinoma. Anaplastic transformation of adenocarcinoma. Cancer 39:2588-2596.
18. Hemmer S, Wasenius V-M, Knuutila S, Franssila K, Joensuu H. 1999. DNA copy number changes in thyroid carcinoma. Am J Pathol 154:1539-1547.
19. Herrmann MA, Hay ID, Bartelt DH. 1991. Cytogenetic and molecular genetic studies of follicular and papillary thyroid tumors. J Clin Invest 88:1596-1604.
20. Hofstra RMW, Landsvater RM, Ceccherinl I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JWM, van Amstel HKP, Romeo G, Lips CJM, Buys CHCM. 1994. A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376.
21. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N, Akiyama M. 1992. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52:1369-1371.
22. Japanese Society of Thyroid Surgery. 1996. General rules for the description of thyroid cancer, 5th ed. Tokyo: Kanehara Publishers. p 4-24.
23. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH. 1994. A cell cycle regulator potentially involve in genesis of many tumor types. Science 264:436-440.
24. Karnik P, Paris M, Williams BR, Casey G, Crowe J, Chen P. 1998. Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Hum Mol Genet 7:895-903.
25. Kitamura Y, Goodfellow PJ, Shimizu K, Nagahama M, Ito K, Kitagawa W, Akasu H, Takami H, Tanaka S, Wells SA Jr. 1997. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene 14:3103-3106.
26. Kitamura Y, Nakata T, Minobe K, Shimizu K, Tanaka S, Fujimori M, Yokoyama Y, Ito K, Onda M, Emi M. 1999a. Ret/PTC3 is the most frequent form of gene rearrangement in papillary thyroid carcinomas in Japan. J Hum Genet 44:96-102.
27. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, Ito K, Ito K Jr, Tanaka S. 1999b. Immediate cause of death in thyroid carcinoma: clinicopathologic analysis of 161 fatal cases. J Clin Endocrinol Metab, in press.
28. Lydiatt WM, Davidson BJ, Schantz SP, Caruana S, Chaganti RS. 1998. 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck 20:113-118.
29. Mulligan LM, Know JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliff L, Ponder BAJ. 1993. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460.
30. Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujita S, Miya A, Mori T, Nishisho I, Takai S. 1992. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83:1293-1298.
31. Nel CJ, van Heerden JA, Goellner JR, Gharib H, McConahey WM, Taylor WF, Grant CS. 1985. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc 60:51-58.
32. Nishiyama RH, Dunn EL, Thompson NW. 1972. Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer 30:113-127.
33. Nobori T, Miura K, Wu DJ, Lois A, Takahashi K, Carson DA. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
34. Ogaki K, Iida A, Kasumi F, Sakamoto G, Akimoto M, Nakamoto Y, Emi M. 1998. Mapping of a new target region of allelic loss to a 6-cM interval at 21q21 in primary breast cancers. Genes Chromosomes Cancer 23:244-247.
35. Segev DL, Saji M, Phillips GS, Westra WH, Takayama Y, Piantadosi S, Smallrirdge RC, Nishiyama RH, Udelsman R, Zeiger MA. 1998. Polymerase chain reaction-based microsatellite polymorphism analysis of follicular and Hürthle cell neoplasmas of the thyroid. J Clin Endocrinol Metab 83:2036-2042.
36. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Hasse VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF. 1993. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800.
37. Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA Jr, Goodfellow PJ. 1996. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol Carcinog 15:5-10.
38. Tung WS, Shevlin DW, Kaleem Z, Tribune DJ, Wells SA Jr, Goodfellow PJ. 1997. Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Genes Chromosomes Cancer 19:43-51.
39. Versteege I, Sevenet N, Lange J, Rousseau-Merck M-F, Ambros P, Handgretinger R, Aurias A, Delattre O. 1998. Truncating mutations of hSNF5/INI1 in aggressive pediatric cancer. Nature 393:203-206.
40. Vogelstein B, Fearon E, Kern S, Hamilton SR, Preisinger AG, Nakamura Y, White R. 1989. Allelotype of colorectal carcinomas. Science 244:207-211.
41. Ward LS, Brenta G, Medvedovic M, Fagin JA. 1998. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab 83:525-530.
42. Zedenius J, Wallin G, Svensson A, Bovee J, Hoog A, Backdahl M, Larsson C. 1996. Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors. Hum Genet 97:299-303.